Table 3.
Characteristics of Patients With and Without Concomitant Glucocorticoid Use (Patients Were Classified Using Current Treatment Regimen)
| No Current Systemic Glucocorticoid Use (n = 385) | Currently Treated with Oral Glucocorticoids (n = 259) | Currently Treated with IV Glucocorticoids (n = 109) | |
|---|---|---|---|
| % all patients (714 patients) | 54% | 36% | 15% |
| Women | 265 (69%) | 159 (61%) | 64 (59%) |
| Age, y | 49.9 ± 13.6 | 48.4 ± 13.3 | 50.6 ± 14.6 |
| TED duration, y | 4.8 ± 5.8 | 3.5 ± 4.1 | 3.4 ± 4.1 |
| Severe disease | 37 (10%) | 45 (17%) | 34 (31%) |
| TED activity | |||
| CAS | 1.9 ± 1.7 | 2.6 ± 1.9 | 3.4 ± 2.0 |
| CAS ≥ 3 | 131 (34%) | 130 (50%) | 74 (68%) |
| Pain symptoms | |||
| Pain in primary gaze (CAS) | 68 (18%) | 67 (26%) | 49 (45%) |
| Pain with eye movement (CAS) | 89 (23%) | 97 (38%) | 57 (52%) |
| Photophobia | 125 (33%) | 113 (44%) | 57 (52%) |
| Vision disturbances | |||
| Blurred/decreased vision | 141 (37%) | 116 (45%) | 66 (61%) |
| Diplopia | 87 (23%) | 74 (29%) | 53 (49%) |
| Color vision changes | 37 (10%) | 40 (15%) | 28 (26%) |
| Structural issues | |||
| Soft-tissue swellinga | 229 (60%) | 194 (75%) | 93 (85%) |
| Proptosis | 250 (65%) | 182 (70%) | 76 (70%) |
| Strabismus | 77 (20%) | 74 (29%) | 48 (44%) |
| Eyelid redness (CAS) | 135 (35%) | 122 (47%) | 62 (57%) |
| Eyelid swelling (CAS) | 131 (34%) | 115 (44%) | 64 (59%) |
| Conjunctival swelling (CAS) | 113 (29%) | 110 (43%) | 62 (57%) |
| Conjunctival redness (CAS) | 213 (55%) | 170 (66%) | 79 (73%) |
| Eyelid retraction | 94 (24%) | 88 (34%) | 46 (42%) |
| Corneal involvement | 98 (26%) | 83 (32%) | 49 (45%) |
| Compressive optic neuropathy | 25 (7%) | 29 (11%) | 26 (24%) |
| Eye muscle involvement | 111 (29%) | 96 (37%) | 58 (53%) |
| Ever treated with (current or prior use) | |||
| Intravenous GCs | 82 (21%) | 71 (27%) | 109 (100%) |
| Oral GCs | 144 (37%) | 259 (100%) | 71 (65%) |
| Periorbital GCs | 42 (11%) | 37 (14%) | 27 (25%) |
| Topical GCs (eye drops) | 220 (57%) | 149 (58%) | 64 (59%) |
| Rituximab and/or tocilizumab | 51 (13%) | 36 (14%) | 34 (31%) |
| Orbital radiation | 29 (8%) | 25 (10%) | 19 (17%) |
| Ocular surgery | 51 (13%) | 18 (7%) | 14 (13%) |
Data presented as mean ± standard deviation or n (%) as appropriate. Thirty-nine patients were currently being treated with both oral and IV glucocorticoids and are included in both GC groups.
aIncludes soft-tissue involvement, eyelid swelling, and/or periorbital swelling.
CAS, clinical activity score; GC, glucocorticoid; TED, thyroid eye disease.